Roche’s next-generation KRAS G12C inhibitor, divarasib, has achieved statistical significance in a global head-to-head Phase III trial against sotorasib and adagrasib for advanced non-small cell lung cancer.
BridgeBio Pharma and Kyowa Kirin announced the publication of positive data from the global Phase 3 PROPEL 3 study of oral infigratinib for pediatric achondroplasia in The New England Journal of Medicine (NEJM), demonstrating unparalleled improvements in annualized height velocity and body proportionality.
Eli Lilly and Company announced results from its Phase 3 BRUIN CLL-322 trial, demonstrating that adding Jaypirca to a venetoclax time-limited regimen cuts the risk of disease progression or death by 45% in previously treated CLL/SLL patients.
Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in earlier-line relapsed or refractory multiple myeloma.
AstraZeneca is advancing its investigational once-daily oral small-molecule GLP-1 receptor agonist, elecoglipron, into a broad Phase III programme after Phase IIb trials demonstrated up to 11.8% weight loss and a 1.9% reduction in HbA1c.
Johnson & Johnson has announced groundbreaking Phase 3 results for Tecvayli Multiple Myeloma Treatment, demonstrating its superiority over standard-of-care therapies in improving overall survival as early as the first relapse.
The Phase III VOLGA trial has reached its primary endpoints, proving that the Imfinzi EV bladder cancer combination delivers historic survival gains in the perioperative setting.
Eli Lilly has released historic long-term data from the Omvoh mirikizumab-mrkz clinical trials, proving that the IL-23p19 antagonist maintains high rates of “disease clearance” through four years of treatment.
Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.
Roche announces positive top-line Enspryng Phase III results from the METEOROID study, demonstrating a significant delay in relapses for patients with MOGAD.
